Skip Nav Destination
Issues
1 August 2011
-
Cover Image
Cover Image
Modification of the glycolipid ligands for natural killer T (NKT) cells might be an efficient approach to improve their stimulatory activity or to shift the proportional release of Th1 and Th2 cytokines. The chemical modified iGb3 analogue, 4‴-dh-iGb3, made by introducing a hydroxyl group at C4 of iGb3 and removing the 4″′ hydroxyl group of the terminal galactose, could increase the stability of the CD1d/antigen/TCR ternary complex and IFN-γ signaling ofNKTcells, and thus stimulate more IFN-γ production by NKT cells. 4‴-dh-iGb3-loaded dendritic cells significantly inhibit growth of subcutaneous melanoma and suppress lung metastasis in C57BL/6 mice. The 4‴-dh-iGb3-loaded dendritic cell vaccine may serve as a potent new NKT-based therapy against tumors. For details, see article by Zhou and colleagues on page 1375.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Spotlight on Clinical Response
Therapeutic Discovery
Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Chun-Te Chen; Hirohito Yamaguchi; Hong-Jen Lee; Yi Du; Heng-Huan Lee; Weiya Xia; Wen-Hsuan Yu; Jennifer L. Hsu; Chia-Jui Yen; Hui-Lung Sun; Yan Wang; Edward T.H. Yeh; Gabriel N. Hortobagyi; Mien-Chie Hung
High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion
Laura Muinelo-Romay; Eva Colas; Jorge Barbazan; Lorena Alonso-Alconada; Marta Alonso-Nocelo; Marta Bouso; Teresa Curiel; Juan Cueva; Urbano Anido; Jeronimo Forteza; Antonio Gil-Moreno; Jaume Reventos; Rafael Lopez-Lopez; Miguel Abal
Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors
Wenle Xia; Zuguo Liu; Rongrong Zong; Leihua Liu; Sumin Zhao; Sarah S. Bacus; Yubin Mao; Jia He; Julia D. Wulfkuhle; Emanuel F. Petricoin, III; Takuya Osada; Xiao-Yi Yang; Zachary C. Hartman; Timothy M. Clay; Kimberly L. Blackwell; Herbert K. Lyerly; Neil L. Spector
Preclinical Development
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Shripad V. Bhagwat; Prafulla C. Gokhale; Andrew P. Crew; Andy Cooke; Yan Yao; Christine Mantis; Jennifer Kahler; Jennifer Workman; Mark Bittner; Lorina Dudkin; David M. Epstein; Neil W. Gibson; Robert Wild; Lee D. Arnold; Peter J. Houghton; Jonathan A. Pachter
Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Aleksandra Bielen; Lara Perryman; Gary M. Box; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Alexa Jury; Sergey Popov; Sharon Gowan; Sebastien Jeay; Florence I. Raynaud; Francesco Hofmann; Darren Hargrave; Suzanne A. Eccles; Chris Jones
Peloruside- and Laulimalide-Resistant Human Ovarian Carcinoma Cells Have βI-Tubulin Mutations and Altered Expression of βII- and βIII-Tubulin Isotypes
Arun Kanakkanthara; Anja Wilmes; Aurora O'Brate; Daniel Escuin; Ariane Chan; Ada Gjyrezi; Janet Crawford; Pisana Rawson; Bronwyn Kivell; Peter T. Northcote; Ernest Hamel; Paraskevi Giannakakou; John H. Miller
Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Daniele G. Soares; Miriana S. Machado; Céline J. Rocca; Virginie Poindessous; Djamila Ouaret; Alain Sarasin; Carlos M. Galmarini; João A.P. Henriques; Alexandre E. Escargueil; Annette K. Larsen
Molecular Medicine in Practice
Rationally Designed Treatment for Solid Tumors with MAPK Pathway Activation: A Phase I Study of Paclitaxel and Bortezomib Using an Adaptive Dose-Finding Approach
Janice M. Mehnert; Antoinette R. Tan; Rebecca Moss; Elizabeth Poplin; Mark N. Stein; Mika Sovak; Kelly Levinson; Hongxia Lin; Michael Kane; Murugesan Gounder; Yong Lin; Weichung Joe Shih; Eileen White; Eric H. Rubin; Vassiliki Karantza
Correction
Advertisement